Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2

Journal of Neuroimmunology

Volumn 73, Issue 1-2, 1997, Pages 183-190

  Petitto, J M ^a   McCarthy, D B ^a   Rinker, C M ^a   Huang, Z ^a   Getty, T ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

behavior; dopamine; interleukin 2; mouse; neurochemistry; receptor

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; FOREBRAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NERVE CELL; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ACOUSTIC STIMULATION; ANIMALS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; FEAR; INTERLEUKIN-2; MALE; MAZE LEARNING; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; PROSENCEPHALON; RECEPTORS, DOPAMINE; SPECIES SPECIFICITY; STARTLE REACTION;

EID: 0031043618     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(96)00196-8     Document Type: Article

References (66)

1. Abramsky, O. and Litvin, Z.J. (1978) Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Prospect. Biol. Med. 22, 104-114.
2. 3H ]dopamine in rat cultured mesencephalic cells. J. Neurochem. 61, 1284-1290.
3. Araujo, D.M., Lapchak, P.A., Chabot, J.G., Nair, N.P. and Quirion, R. (1989a) Characteristics and possible role of growth factor and lymphokine receptors in the regulation of cholinergic function in the mammalian brain. Prog. Clin. Biol. Res. 317, 423-436.
4. Araujo, D.M., Lapchak, P.A. Collier, B. and Quirion, R. (1989b) Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: Interaction with the cholinergic system. Brain Res. 498, 257-266.
5. Banks, W.A. and Kastin, A.J. (1992) The interleukins-1α, -1β and -2 do not acutely disrupt the murine blood-brain barrier. Int. J. Immunopharmacol. 4, 629-636.
6. Benveniste, E.N. and Merrill, J.E. (1986) Stimulation of oligodendroglial proliferation and maturation by interleukin-2. Nature 321, 610-613.
7. Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C., Lotze, M.T., Chang, A.E., Rosenstein, D. and Rosenberg, S.A. (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107, 293-300.
8. De Sarro, G.B., Masuda, Y., Ascioti, C., Audino, M.G. and Nistico, G. (1990). Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone. Neuropharmacology 29, 167-179.
9. Eizenberg, O., Faber-Elman, A., Lotan, M. and Schwartz, M. (1995) Interleukin-2 transcripts in human and rodent brains: Possible expression by astrocytes. J. Neurochem. 64, 1928-1936.
10. Ellison, M.D., Krieg, R.J. and Povlishock, J.T. (1990) Differential central nervous system responses following single and multiple recombinant IL-2 infusions. J. Neuroimmunol. 28, 249-260.
11. Ellison, M.D., Povlishock, J.T. and Merchant, R.E. (1987) Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusions. Cancer Res. 47, 5765-5770.
12. Florijn, W.J., De-Boer, T., Tonnaer, J.A., Van-Nispen, J.W. and Versteeg, D.H. (1991) ACTH/MSH-like peptides inhibit the binding of dopaminergic ligands to the dopamine D2 receptor in vitro. Eur. J. Pharmacol. 207, 43-50.
13. Florijn, W.J., De-Boer, T., Tonnaer, J.A. and Versteeg, D.H. (1992) Characterization of the inhibitory effect of adrenocorticotropin/melanocyte-stimulating hormone-like peptides on the binding of dopamine receptor ligands to the dopamine D2 receptor in vitro. J. Pharmacol. Exp. Ther. 263, 787-792.
14. Ganguli, R., Brar, J.S., Chengappa, K.N., Yang, Z.W., Nimgaonkar, V.L. and Rabin, B.S. (1993) Autoimmunity in schizophrenia: A review of recent findings. Ann. Med. 25, 489-496.
15. Ganguli, R., Brar, J.S., Chengappa, K.N., DeLeo, M., Yang, Z.W., Shurin, G. and Rabin, B.S. (1995) Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch. Gen. Psychiatry 52, 668-678.
16. Geyer, M.A., Wilkinson, L.S., Humby, T. and Robbins, T.W. (1993) Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol. Psychiatry 34, 361-372.
17. Hanisch, U.K., Seto, D. and Quirion, R. (1993) Modulation of hipppocampal acetylcholine release: Potent central action of interleukin-2. J. Neurosci. 13, 3368-3374.
18. Herdon, H., Strupish, J. and Nahorski, S.R. (1985) Differences between the release of radiolabelled and endogenous dopamine from superfused rat brain slices: Effects of depolarizing stimuli, amphetamine and synthesis inhibition. Brain Res. 348, 309-320.
19. Herdon, H., Strupish, J. and Nahorski, S.R. (1987) Endogenous dopamine release from rat striatal slices and its regulation by D-2 autoreceptors: Effects of uptake inhibitors and synthesis inhibition. Eur. J Pharmacol. 138, 69-76.
20. 3H ]mazindol binding sites in rat striatum by dopaminergic agents. Eur. J. Pharmacol. 250, 261-266.
21. Ikegami, H. and Prasad, C. (1990) Neuropeptide-dopamine interactions. V. Cyclo(His-Pro) regulation of striatal dopamine transporter complex. Peptides 11, 145-148.
22. Kashima, N., Nishi-Takaoka, C., Fujita, T., Taki, S., Yamada, G., Hamuro, J. and Taniguchi, T., (1985) Unique structure of murine interleukin-2 as deduced from cloned cDNAs. Nature 313, 402-404.
23. Kilts, C.D., Breese, G.R. and Mailman, R.B. (1981) Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high performance liquid chromatography with electrochemical detection. J. Chromatogr. A 225, 347-357.
24. Kluter, H., Vieregge, P., Stolze, H. and Kirchner, H. (1995) Defective production of interleukin-2 in patients with idiopathic Parkinson's disease. J. Neurol. Sci. 133, 134-139.
25. Kono, T., Doi, T., Yamada, G., Hatakeyama, M., Minamoto, S., Tsudo, M., Miyasaka, M., Miyata, T. and Taniguchi, T. (1990) Murine interleukin-2 receptor β chain: Dysregulated gene expression in lymphoma line EL-4 caused by a promoter insertion. Proc. Natl. Acad. Sci. U.S.A. 87, 1806-1810.
26. Lapchak, P.A., Araujo, D.M., Quirion, R and Beaudet, A. (1991) Immunoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivty) in the rat brain. Neuroscience 44, 173-184.
27. Lapchak, P.A. (1992) A role for interleukin-2 in the regulation of stratal dopaminergic function. Neuroreport 3, 165-168.
28. LeMoal, M. and Simon, H. (1991) Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol. Rev. 71, 155-234.
29. Li, X.M., Hedlund, P.B. and Fuxe, K. (1994) Strong effects of NT/NN peptides on DA D2 receptors in rat neostriatal sections. Neuroreport 15, 1621-1624.
30. Licinio, J., Seibyl, J.P., Altemus, M., Charney, D.S. and Krystal, J.H. (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry 150, 1408-1410.
31. Lister, R.G. (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92, 180-85.
32. Maes, M., Bosmans, E., Calabrese, J. Smith, R. and Meltzer, H.Y. (1995a) Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29, 141-152.
33. Maes, M., Meltzer, H.Y., Buckley, P. and Bosmans, E. (1995b) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur. Arch. Psychiatry Clin. Neurosci. 244, 325-329.
34. McAllister, C.G., van-Kammen, D.P., Rehn, T.J., Miller, A.L., Gurklis, J., Kelley, M.E., Yao, J. and Peters, J.L. (1995) Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status. Am. J. Psychiatry 152, 1291-1297.
35. Merrill, J.E. (1990) Interleukin-2 effects in the central nervous system. Ann. N.Y. Acad. Sci. 594, 188-199.
36. Miller, J., Malek, T.R., Leonard, W.J., Greene, W.C., Shevach, E.M. and Germain, R.N. (1985). Nucleotide sequence and expression of a mouse interleukin 2 receptor cDNA. J. Immunol. 134, 4212-4217.
37. Minchin, M.C.W. (1980) Veratrum alkaloids as transmitter-releasing agents. J. Neurosci. Methods 2, 111-121.
38. Naito, Y., Fukata, J., Tominaga, T., Masui, Y., Hirai, Y., Murakami, N., Tamai, S., Mori, K. and Imura, H. (1989) Adrenocorticotropic hormone-releasing activities of interleukins in a homologous in vivo system. Biochem. Biophys. Res Commun. 164, 1262-1267.
39. Nistico, G. and De Sarro, G. (1991) Is interleukin 2 a neuromodulator in the brain? Trends Neurosci. 14, 146-150.
40. Nistico, G. (1993) Communications among central nervous system, neuroendocrine and immune systems. Prog. Neurobiol. 40, 463-475.
41. Otero, G.C. and Merrill, J.E. (1995) Molecular cloning of IL-2Rα, IL-2Rβ and IL-2Rγ cDNA from a human oligodendroglioma cell line: Presence of IL-2R mRNAs in the human central nervous system. Glia 14, 295-302.
42. Peng, R.Y., Mansbach, R.S., Braff, D.L. and Geyer, M.A. (1990) A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology 3, 211-218.
43. Petitto, J.M, Lysle, D.T., Gariepy, J-L., Clubb, P.A., Cairns, R.B. and Lewis, M.H. (1993) Genetic differences in social behavior: Relation to natural killer cell function and susceptibility to tumor development. Neuropsychopharmacology 8:35-43.
44. Petitto, J.M. and Huang, Z. (1994) Molecular cloning of a partial cDNA of the interleukin-2 receptor-β in normal mouse brain: In situ localization in the hippocampus and expression by neuroblastoma cells. Brain Res. 650, 140-145.
45. Petitto, J.M. and Huang, Z. (1995) Molecular cloning of the coding sequence of an interleukin-2 receptor α subunit cDNA in murine brain. J. Neuroimmunol. 59, 135-141.
46. c) from murine forebrain and human hippocampus: Expression by astrocytes and neuroblastoma cells. Soc. Neurosci. Abstr. 22, 1353.
47. Raber, J. and Bloom, F.E. (1994) IL-2 induces vasopressin release from the hypothalamus and the amygdala: Role of nitric oxide-mediated signaling. J. Neurosci. 14, 6187-6195.
48. Raber, J., Koob, G.F. and Bloom, F.E. (1995) Interleukin-2 (IL-2) induces corticotrophin-releasing factor (CRF) release from the amygdala and involves nitric-oxide mediated signaling: Comparison with the hypothalamic response. J. Pharm. Exp. Ther. 272, 815-824.
49. Rapaport, M.H., Torrey, E.F., McAllister, C.G., Nelson, D.L., Pickar, D. and Paul, S.M. (1993) Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur. Arch. Psychiatry Clin. Neurosci. 243, 7-10.
50. Rapaport, M.H. and Lohr, J.B. (1994) Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 90, 311-315.
51. 3H ]raclopride binding to neostriatal dopamine D2 receptors: Role of disulfide and sulfhydryl groups. Neurochem. Res. 17, 749-759.
52. Robbins, T.W. and Everitt, B.J. (1992) Functions of dopamine in the dorsal and ventral striatum. Semin. Neurosci. 4, 119-127.
53. Rosenstein, M., Ettinghausen, S.E. and Rosenberg, S.A. (1986) Etravasation of intravascular fluid mediated by the systemic the systemic administration of recombinant interleukin-2. J. Immunol. 137, 1735-1742.
54. Saneto, R.P., Altman, A., Knobler, R.L., Johnson, H.M. and de Vellis, J. (1986) Interleukin 2 mediates the inhibition of oligodendrocyte progenitor cell proliferation in vitro. Proc. Natl. Acad. Sci. U.S.A. 83, 9221-9225.
55. 3H ]-dopamine binding in striatum without inhibiting dopamine sensitive adenylate cyclase. Neurochem. Int. 6, 117-121.
56. 3H ]SCH23390 in rat brain: Regional distribution and effects of assay conditions and GTP suggest interactions at a D1-like dopamine receptor. J. Neurochem. 45, 1601-1611.
57. Smith, E.M. and Blalock, J.E. (1981) Human lymphocyte production of corticotrophin and endorphin-like substances. Proc. Natl. Acad. Sci. U.S.A. 78, 7530-7534.
58. Smith, E.M., Dion, L.D. and Blalock, J.E. (1985) Opiate receptor mediated effects of IFN-alpha and lymphocyte derived endorphin-like peptides. Prog. Clin. Biol. Res. 192, 259-264.
59. Swerdlow, N.R., Braff, D.L., Masten, V.L. and Geyer, M.A. (1990) Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharmacology 101, 414-420.
60. Swerdlow, N.R., Braff, D.L., Taaid, N. and Geyer, M.A. (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 51, 139-154.
61. Trullas, R. and Skolnick, P. (1993) Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology 111, 327-331.
62. Villemain, F., Chatenoud, L., Galinowski, A., Homo-Delarche, F., Ginestet, D., Loo, H., Zarifian, E. and Bach, J.F. (1989) Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatr. 146, 609-616.
63. Waguespack, P.J., Banks, W.A. and Kastin, A. (1994) Interleukin-2 does not cross the blood-brain barrier by a saturable transport system. Brain Res. Bull. 34, 103-109.
64. Watts, R.G., Wright, J.L., Atkinson, L.L. and Merchant, R.E. (1988) Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin-2. Neurosurgery 25, 202-208.
65. West, W.H., Tauer, K.W., Yannelli, J.R., Marshall, G.D., Orr, D.W., Thurman, G.B. and Oldham, R.K. (1987). Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316, 898-905.
66. Zalcman, S., Green-Johnson, J.M., Murray, L., Nance, D.M., Dyck, D., Anisman, H. and Greenberg, A.H. (1994) Cytokine specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 643, 40-49.